NeuroOne Medical Technologies Reports Preliminary FY25 Results Of $9.1M Product Revenue And $6.6M Cash On Hand

Benzinga
Oct 07, 2025

Preliminary Results

On October 6, 2024, the Company reported the following preliminary unaudited fiscal year 2025 financial and operational results:

 Achieved annual total product revenue of approximately $9.1 million.
 Cash and cash equivalents of approximately $6.6 million at September 30, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10